{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:03:29Z","timestamp":1780121009264,"version":"3.54.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-025-00759-0","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T09:47:09Z","timestamp":1766828829000},"page":"249-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A New Avenue for the Long-Term Upstream Inhibition of the Renin-Angiotensin-Aldosterone System by Inhibiting Angiotensinogen RNA."],"prefix":"10.1007","volume":"33","author":[{"given":"Giovanna","family":"Gallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Tocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Speranza","family":"Rubattu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-8380","authenticated-orcid":false,"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"759_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-025-02229-5","author":"SI Miura","year":"2025","unstructured":"Miura SI, Matsuo Y, Seumatsu Y. Renin-angiotensin-aldosterone system and its relation to hypertension. Hypertens Res. 2025. https:\/\/doi.org\/10.1038\/s41440-025-02229-5.","journal-title":"Hypertens Res"},{"key":"759_CR2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41440-021-00643-z","volume":"44","author":"T Ghatage","year":"2021","unstructured":"Ghatage T, Goyal SG, Dhar A, Bhat A. Novel therapeutics for the treatment of hypertension and its associated complications: peptide\u2014and nonpeptide-based strategies. Hypertens Res. 2021;44:740\u201355.","journal-title":"Hypertens Res"},{"key":"759_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.kisu.2021.11.002","volume":"12","author":"CM Ferrario","year":"2022","unstructured":"Ferrario CM, Groban L, Wang H, Sun X, VonCannon JL, Wright KN, et al. The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts. Kidney Int Suppl. 2022;12:36\u201347.","journal-title":"Kidney Int Suppl"},{"key":"759_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jchf.2022.06.005","volume":"10","author":"T Kahlon","year":"2022","unstructured":"Kahlon T, Carlisle S, Otero Mostacero D, Williams N, Trainor P, DeFilippis AP. Angiotensinogen: more than its downstream products: evidence from population studies and novel therapeutics. JACC Heart Fail. 2022;10:699\u2013713.","journal-title":"JACC Heart Fail"},{"key":"759_CR5","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/HYPERTENSIONAHA.115.03624","volume":"66","author":"CN Young","year":"2015","unstructured":"Young CN, Davisson RL. Angiotensin-II, the brain, and hypertension: an update. Hypertension. 2015;66:920\u20136.","journal-title":"Hypertension"},{"key":"759_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/VHRM.S337640","volume":"18","author":"G Gallo","year":"2022","unstructured":"Gallo G, Volpe M, Rubattu S. Angiotensin receptor blockers in the management of hypertension: a real-world perspective and current recommendations. Vasc Health Risk Manag. 2022;18:507\u201315.","journal-title":"Vasc Health Risk Manag"},{"key":"759_CR7","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1093\/eurheartj\/ehab489","volume":"42","author":"M Volpe","year":"2021","unstructured":"Volpe M, Gallo G. Sacubitril\/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike? Eur Heart J. 2021;42:3753\u20135.","journal-title":"Eur Heart J"},{"key":"759_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","volume":"124","author":"M Burnier","year":"2019","unstructured":"Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124:1124\u201340.","journal-title":"Circ Res"},{"key":"759_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1161\/HYPERTENSIONAHA.118.11084","volume":"72","author":"H Nakagami","year":"2018","unstructured":"Nakagami H, Morishita R. Recent advances in therapeutic vaccines to treat hypertension. Hypertension. 2018;72:1031\u20136.","journal-title":"Hypertension"},{"key":"759_CR10","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1161\/ATVBAHA.123.319897","volume":"43","author":"D Ye","year":"2023","unstructured":"Ye D, Cruz-L\u00f3pez EO, Tu HC, Zlatev I, Danser AHJ. Targeting angiotensinogen with N-acetylgalactosamine-conjugated small interfering RNA to reduce blood pressure. Arterioscler Thromb Vasc Biol. 2023;43:2256\u201364.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"759_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40292-024-00634-4","volume":"31","author":"G Nardoianni","year":"2024","unstructured":"Nardoianni G, Pala B, Scoccia A, Volpe M, Barbato E, Tocci G. Systematic review article: new drug strategies for treating resistant hypertension-the importance of a mechanistic, personalized approach. High Blood Press Cardiovasc Prev. 2024;31:99\u2013112.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"759_CR12","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","volume":"136","author":"JK Nair","year":"2014","unstructured":"Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, et al. Multivalent N-acetyl galactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi mediated gene silencing. J Am Chem Soc. 2014;136:16958\u20137169.","journal-title":"J Am Chem Soc"},{"key":"759_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/01.HYP.4.2.185","volume":"4","author":"J Gardes","year":"1982","unstructured":"Gardes J, Bouhnik J, Clauser E, Corvol P, Menard J. Role of angiotensinogen in blood pressure homeostasis. Hypertension. 1982;4:185\u20139.","journal-title":"Hypertension"},{"key":"759_CR14","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/01.HYP.29.6.1240","volume":"29","author":"LM de Lannoy","year":"1997","unstructured":"de Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MADH. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart local production of angiotensin I. Hypertension. 1997;29:1240\u201351.","journal-title":"Hypertension"},{"key":"759_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0014-5793(98)01145-4","volume":"436","author":"RMA Streatfeild-James","year":"1998","unstructured":"Streatfeild-James RMA, Williamson D, Pike RN, Tewksbury D, Carrell RW, Coughlin PB. Angiotensinogen cleavage by renin: importance of a structurally constrained N-terminus. FEBS Lett. 1998;436:267\u201370.","journal-title":"FEBS Lett"},{"key":"759_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/01.RES.52.3.328","volume":"52","author":"HC Herrmann","year":"1983","unstructured":"Herrmann HC, Dzau VJ. The feedback regulation of angiotensinogen production by components of the renin-angiotensin system. Circ Res. 1983;52:328\u201334.","journal-title":"Circ Res"},{"key":"759_CR17","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/cvr\/cvae136","volume":"120","author":"U Makhmudova","year":"2024","unstructured":"Makhmudova U, Steinhagen-Thiessen E, Volpe M, Landmesser U. Advances in nucleic acid-targeted therapies for cardiovascular disease prevention. Cardiovasc Res. 2024;120:1107\u201325.","journal-title":"Cardiovasc Res"},{"key":"759_CR18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.117.09755","volume":"70","author":"AE Mullick","year":"2017","unstructured":"Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP, Crooke RM. Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury. Hypertension. 2017;70:566\u201376.","journal-title":"Hypertension"},{"key":"759_CR19","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","volume":"26","author":"DJ Foster","year":"2018","unstructured":"Foster DJ, Brown CR, Shaikh S, Trapp C, Schlegel MK, Qian K, et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol Ther. 2018;26:708\u201317.","journal-title":"Mol Ther"},{"issue":"Supplement_2","key":"759_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.2830","volume":"44","author":"J Johannes Wikstrom","year":"2023","unstructured":"Johannes Wikstrom J, Liang J, Cao H, Gao S, Gan L. Targeting liver angiotensinogen using a GalNAc-siRNA improves cardiac remodeling in spontaneously hypertensive rats. Eur Heart J. 2023;44(Supplement_2):ehad655.2830.","journal-title":"Eur Heart J"},{"key":"759_CR21","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","volume":"73","author":"E Uijl","year":"2019","unstructured":"Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, et al. Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen. Hypertension. 2019;73:1249\u201357.","journal-title":"Hypertension"},{"key":"759_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/MS9.0000000000002696","volume":"87","author":"E Siddiqui","year":"2025","unstructured":"Siddiqui E, Siddiqui AH, Moeed A, Laique F, Najeeb H, Al Hasibuzzaman M. Advancing hypertension management: the role of zilebesiran as an siRNA therapeutic agent. Ann Med Surg. 2025;87:577\u201382.","journal-title":"Ann Med Surg"},{"key":"759_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389:228\u201338.","journal-title":"N Engl J Med"},{"key":"759_CR24","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1093\/eurheartj\/ehad593","volume":"44","author":"G Liuzzo","year":"2023","unstructured":"Liuzzo G, Volpe M. Silencing liver angiotensinogen synthesis as a novel approach to hypertension management: promises and challenges. Eur Heart J. 2023;44:4217\u20139.","journal-title":"Eur Heart J"},{"key":"759_CR25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jama.2024.0728","volume":"331","author":"GL Bakris","year":"2024","unstructured":"Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, et al. RNA interference with Zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA. 2024;331:740\u20139.","journal-title":"JAMA"},{"key":"759_CR26","unstructured":"Desai AS, Karns AD, Badariene J, Aswad A, Neutel JM, Kazi F, Park W, Stiglitz D, Makarova N, Havasi A, Zappe DH, Saxena M; 2025 KARDIA-2 study group. add-on treatment with zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial. JAMA. 28:e256681"},{"issue":"Suppl 1","key":"759_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0001020524.16638.68","volume":"42","author":"A Havasi","year":"2024","unstructured":"Havasi A, Pagidipati N, Bakris G, Weber M, Bengus M, Daga S, et al. KARDIA-3 study design: zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension inadequately controlled by standard of care antihypertensives. J Hypertens. 2024;42(Suppl 1):e120.","journal-title":"J Hypertens"},{"key":"759_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10557-024-07656-z","volume":"39","author":"M Owais","year":"2025","unstructured":"Owais M, Akhtar A, Bhattacharjee P. Transforming hypertension treatment: Zilebesiran\u2019s possible impact. Cardiovasc Drugs Ther. 2025;39:237\u20138.","journal-title":"Cardiovasc Drugs Ther"},{"key":"759_CR29","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1172\/JCI99417","volume":"130","author":"N Haase","year":"2020","unstructured":"Haase N, Foster DJ, Cunningham MW, Bercher J, Nguyen T, Shulga-Morskaya S, et al. RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models. J Clin Invest. 2020;130:2928\u201342.","journal-title":"J Clin Invest"},{"key":"759_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.644","volume":"8","author":"N Buawangpong","year":"2020","unstructured":"Buawangpong N, Teekachunhatean S, Koonrungsesomboon N. Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin- converting enzyme inhibitors or angiotensin II receptor blockers: a systematic review and meta-analysis. Pharmacol Res Perspect. 2020;8:e00644.","journal-title":"Pharmacol Res Perspect"},{"key":"759_CR31","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/17512433.2023.2277330","volume":"16","author":"ML Addison","year":"2023","unstructured":"Addison ML, Ranasinghe P, Webb DJ. Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension. Expert Rev Clin Pharmacol. 2023;16:1025\u201333.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"759_CR32","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/HYPERTENSIONAHA.122.19430","volume":"80","author":"ML Addison","year":"2023","unstructured":"Addison ML, Ranasinghe P, Webb DJ. Novel pharmacological approaches in the treatment of hypertension: a focus on RNA-based therapeutics. Hypertension. 2023;80:2243\u201354.","journal-title":"Hypertension"},{"key":"759_CR33","doi-asserted-by":"crossref","unstructured":"Patel VB, Zhong J, Grant MB, Oudit GY. Role of the ACE2\/angiotensin 1\u20137 axis of the renin\u2013angiotensin system in heart failure. Circ Res. 2016;118:1313.","DOI":"10.1161\/CIRCRESAHA.116.307708"},{"key":"759_CR34","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1093\/nar\/gkac539","volume":"50","author":"MK Schlegel","year":"2022","unstructured":"Schlegel MK, Janas MM, Jiang Y, Barry JD, Davis W, Agarwal S, et al. From bench to bedside: improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization. Nucleic Acids Res. 2022;50:6656\u201370.","journal-title":"Nucleic Acids Res"},{"key":"759_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102542","volume":"36","author":"ZA Huang","year":"2025","unstructured":"Huang ZA, Ji GS, Yang S, Yang Y, Wu YC, Tian ZK, et al. Design, pharmacology, and toxicology of a novel chemically modified siRNA targeting hepatic angiotensinogen. Mol Ther Nucleic Acids. 2025;36:102542.","journal-title":"Mol Ther Nucleic Acids."},{"key":"759_CR36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40292-024-00696-4","volume":"32","author":"K Callender","year":"2025","unstructured":"Callender K, Ogieuhi IJ, Ajekiigbe VO, Adeyemi BA, Agbo CE, Falayi TA, et al. Renal denervation as a novel therapeutic approach for resistant hypertension: mechanisms, efficacy and future directions. High Blood Press Cardiovasc Prev. 2025;32:227\u201354.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"759_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nbt.4136","volume":"36","author":"I Zlatev","year":"2018","unstructured":"Zlatev I, Castoreno A, Brown CR, Qin J, Waldron S, Schlegel MK, et al. Reversal of siRNA-mediated gene silencing in vivo. Nat Biotechnol. 2018;36:509\u201311.","journal-title":"Nat Biotechnol"},{"key":"759_CR38","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/HYPERTENSIONAHA.124.22878","volume":"81","author":"D Ye","year":"2024","unstructured":"Ye D, Cruz-L\u00f3pez EO, Veghel RV, Garrelds IM, Kasper A, Wassarman K, et al. Counteracting angiotensinogen small-interfering RNA-mediated antihypertensive effects with REVERSIR. Hypertension. 2024;81:1491\u20139.","journal-title":"Hypertension"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00759-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-025-00759-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00759-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:42:51Z","timestamp":1780119771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-025-00759-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1007\/s40292-025-00759-0","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to disclose with regard the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}